Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit tosses $59m trade secrets judgment against EOFlow

29 May 2026 A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.

Careers

Neal Gerber Eisenberg expands in Chicago with new litigator

28 May 2026 The Chicago firm has added a partner with experience across patent litigation and strategic counselling for clients in the pharma, biotech, and advanced technology sectors.

Europe

European court backs AstraZeneca unit in blood cancer combo dispute

28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.

More features

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Part I: Ozempic goes generic as Novo’s key patent expires

Emotional Perception: What next for patent holders?

Semaglutide patent battle heats up with new blow for Novo in India

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features